Utide Biotechnology, also referred to as Guizhou MTpeptides Biotechnology Co., Ltd. or Guizhou Utide Biotechnology Co., Ltd., is a Chinese biotechnology company focused on the research, development and manufacturing of peptide active pharmaceutical ingredients (APIs). The company specialises particularly in GLP-1 peptide therapeutics used in obesity, diabetes and metabolic disease treatment.

Headquartered in Guizhou Province, China, Utide operates as a peptide API manufacturer and expanding CDMO/CRDMO partner serving global pharmaceutical and biotechnology markets. The company’s core team reportedly brings more than 20 years of peptide drug development experience, supporting both catalogue peptide products and customised peptide development programmes.

Utide focuses heavily on next-generation metabolic disease therapies, including GLP-1 receptor agonists and multi-target incretin peptides. Its portfolio includes compounds such as semaglutide, tirzepatide, retatrutide and cagrilintide, alongside other therapeutic peptides targeting gastrointestinal, endocrine and metabolic disorders.

The company positions itself as a quality-driven peptide manufacturing partner with advanced synthesis capabilities, regulatory documentation support and global logistics infrastructure. Utide states that its operations are supported by ISO 9001, ISO 14001 and ISO 45001 certifications, and it is actively developing GMP manufacturing infrastructure to support international pharmaceutical markets.

Utide also provides custom peptide synthesis, peptide drug research and regulatory support services, enabling pharmaceutical companies to outsource peptide development and manufacturing workflows.

Key products and services

GLP-1 peptide APIs

• Semaglutide
• Tirzepatide
• Retatrutide
• Cagrilintide
• Multi-target incretin peptide APIs for obesity and diabetes applications

Custom peptide synthesis

• Custom peptide manufacturing
• Research and development peptide synthesis
• Tailored peptide solutions for pharmaceutical development

Peptide drug development services

• Peptide drug research support
• Process development and optimisation
• CRDMO/CDMO partnership services

Regulatory and compliance support

• Drug Master File (DMF) preparation and submission
• Regulatory documentation and CMC compilation
• International compliance support for peptide APIs

Manufacturing and GMP infrastructure

• Peptide synthesis and purification systems
• Lyophilisation and chromatography capabilities
• Planned GMP manufacturing expansion for commercial production

Global supply chain and logistics

• Temperature-controlled pharmaceutical logistics
• International API shipping and compliance documentation
• Global distribution support for peptide products

By combining peptide synthesis expertise with growing CDMO capabilities and a strong focus on GLP-1 therapeutics, Utide Biotechnology is positioning itself as an emerging global supplier of peptide APIs and development services. Its emphasis on metabolic disease therapies, regulatory compliance and scalable manufacturing infrastructure supports pharmaceutical companies seeking specialised peptide development and supply partners.